Treating cancer with selective CDK4/6 inhibitors
Treating cancer with selective CDK4/6 inhibitors
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Key Points
The actions of cyclin-dependent kinases (CDK) 4/6, through phosphorylation of retinoblastoma-associated protein 1 (RB1) are pivotal in the transition from G1 to S phase in many cancer cells
The effectiveness of non-selective inhibition of CDKs is hampered by toxicities, selective CDK4/6 inhibition results in fewer toxicities and al...
Alternative Titles
Full title
Treating cancer with selective CDK4/6 inhibitors
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1808690164
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1808690164
Other Identifiers
ISSN
1759-4774
E-ISSN
1759-4782
DOI
10.1038/nrclinonc.2016.26
